modernatx

Documents about modernatx

• W911QY20C0100 — MODERNATX, INC. — Department of Defense ($8,204,906,278)#604311USAspending
• 75A50120C00034 — MODERNATX, INC. — Department of Health and Human Services ($1,754,345,480)#604705USAspending
• A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults#154721ClinicalTrials.gov
• Use of Wearable Digital Sensors After mRNA Vaccination in Adults#1088957ClinicalTrials.gov
• A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults#628570ClinicalTrials.gov
• A Study of the Effectiveness of Moderna COVID-19 Vaccine#1197675ClinicalTrials.gov
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults#174932ClinicalTrials.gov
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older#314407ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants#859818ClinicalTrials.gov
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age#369874ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects#1350749ClinicalTrials.gov
• A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas#230484ClinicalTrials.gov
• Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults#290839ClinicalTrials.gov
• A Study of Updated mRNA Seasonal Influenza Vaccines#1396550ClinicalTrials.gov
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults#1246984ClinicalTrials.gov
• Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia#1280013ClinicalTrials.gov
• A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults#256959ClinicalTrials.gov
• Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants#261365ClinicalTrials.gov
• A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age#290843ClinicalTrials.gov
• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)#341990ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults#825540ClinicalTrials.gov
• Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults#847716ClinicalTrials.gov
• A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19#136411ClinicalTrials.gov
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults#369868ClinicalTrials.gov
• Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older#471508ClinicalTrials.gov
• mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)#915391ClinicalTrials.gov
• Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants#1369750ClinicalTrials.gov
• Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure#867408ClinicalTrials.gov
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19#329585ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors#993487ClinicalTrials.gov
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age#314384ClinicalTrials.gov
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age#992948ClinicalTrials.gov
• A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age#268075ClinicalTrials.gov
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults#838330ClinicalTrials.gov
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age#857668ClinicalTrials.gov
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients#874707ClinicalTrials.gov
• A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants#901804ClinicalTrials.gov
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)#980993ClinicalTrials.gov
• A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults#1211739ClinicalTrials.gov
• A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age#1364326ClinicalTrials.gov
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations#903646ClinicalTrials.gov
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations#1339975ClinicalTrials.gov
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults#1398427ClinicalTrials.gov
• A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia#1139085ClinicalTrials.gov
• A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)#1259604ClinicalTrials.gov
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine#839686ClinicalTrials.gov
• A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age#918725ClinicalTrials.gov
• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE#840130ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age#911744ClinicalTrials.gov
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age#1164673ClinicalTrials.gov